07 dec: 5 fede bordlamper
09 dec: Skandalen ingen taler om
07-12-2010 13:00:00

Ultralife Corporation Receives $5.5 Million Land Warrior Battery and Charging System Contract

Relateret indhold

Ultralife Corporation (NASDAQ: ULBI) has received a contract valued at

approximately $5.5 million to supply its suite of Land Warrior Lithium

non-rechargeable batteries and rechargeable Lithium Ion batteries and

charging systems from a major international defense contractor for use

with the Land 200 Battle Management System by the Australian military.

Deliveries are expected to begin in the first quarter of 2011 and be

completed by the fourth quarter of 2012.

“Our capabilities in developing and supplying technically-advanced

defense communications and power systems, which we have demonstrated to

the U.S. Department of Defense across a wide variety of military

programs, are increasingly being recognized by our international

allies,” said John D. Kavazanjian, president and chief executive

officer. “In this case, our Land Warrior product suite will be used to

support the Australian military’s Land 200 Battle Management System, a

program for which we are already supplying our A320 RF pocket

amplifiers.”

Land Warrior is an integrated, modular fighting system that uses

technology to enhance individual soldiers’ close-combat tactical

awareness, lethality and survivability. The system includes

weapon-mounted sensors, an integrated helmet assembly, a

communications-navigation computer system and software for

friendly-force tracking and command/control programs, and it

incorporates Ultralife’s battery models LI-145, LI-80, LM-145 and CH0006

Charger and Adapters.

About Ultralife Corporation

Ultralife Corporation, which began as a battery company, serves its

markets with products and services ranging from portable and standby

power solutions to communications and electronics systems. Through its

engineering and collaborative approach to problem solving, Ultralife

serves government, defense and commercial customers across the globe.

Headquartered in Newark, New York, the company’s business segments

include: Battery & Energy Products, Communications Systems and Energy

Services. Ultralife has operations in North America, Europe and Asia.

For more information, visit www.ultralifecorp.com

This press release may contain forward-looking statements based on

current expectations that involve a number of risks and uncertainties.

The potential risks and uncertainties that could cause actual results to

differ materially include: worsening global economic conditions,

increased competitive environment and pricing pressures, disruptions

related to restructuring actions and delays. The Company cautions

investors not to place undue reliance on forward-looking statements,

which reflect the Company’s analysis only as of today’s date. The

Company undertakes no obligation to publicly update forward-looking

statements to reflect subsequent events or circumstances. Further

information on these factors and other factors that could affect

Ultralife's financial results is included in Ultralife's Securities and

Exchange Commission (SEC) filings, including the latest Annual Report on

Form 10-K.

Ultralife Corporation

Philip

Fain, 315-332-7100

pfain@ulbi.com

or

Investor

Relations:

Lippert/Heilshorn & Associates,

Inc.

Jody Burfening, 212-838-3777

jburfening@lhai.com

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Vestas vil til tops i Indien - citat

25-04-2017 15:02:38
Tirsdag blev Vestas' seneste 2 megawatts-vindmølle lanceret i New Delhi, og Clive Turton, der er chef for Vestas' Asien-afdeling slog fast, at den danske vindmølleproducent vil være førende i Indien.- Inden er det mest vigtige og afgørende marked i Asien-Stillehavet-regionen. Vi mener, vi har den bedste teknologi, og nu kan Vestas komme på førstepladsen her i landet, sagde Clive Turton til branche..

Novo: Amerikansk rival har stærkt diabetessalg i første kvartal

25-04-2017 12:33:38
En af Novo Nordisks største konkurrenter - det amerikanske medicinalselskab Eli Lilly - solgte mere diabetesmedicin i første kvartal end ventet af analytikerne. Også indtjeningen overrasker til den positive side.Eli Lilly kom ud af kvartalet med et nettooverskud på 1040 mio. dollar mod 882 mio. dollar i samme periode sidste år. Det justerede resultat per aktie landede på 0,98 dollar, hvilket var e..

Aktier/åbning: C20 Cap fortsætter kursen mod rekord

25-04-2017 09:26:57
Der er tirsdag morgen stadig en smule brændstof tilbage i det franske valgresultat til nye stigninger på aktiemarkederne.Ingen af de danske eliteaktier gør dog særligt væsen af sig, og man skal ud blandt sidepapirerne for at finde større bevægelser til blandt andet FLSmidth og Össur. FLS-aktien stiger efter godt nyt fra en konkurrent, mens Össur er i modvind oven på en sænket anbefaling fra Nordea..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Bankerne i fokus på ny plusdag
2
Vestas vil til tops i Indien - citat
3
Novo: Amerikansk rival har stærkt diabetessalg i første kvartal
4
Tirsdagens aktier: Novo og Jyske lå pænt i indeks i rekord igen - KORR
5
DSV: Fransk kapitalfond satser på kursfald før regnskab

Relaterede aktiekurser

Ultralife Corporation 5,65 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. april 2017 08:04:54
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170403.1 - EUROWEB4 - 2017-04-26 08:04:54 - 2017-04-26 08:04:54 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x